Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)
Brief Summary: The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MLTA3698A, Drug: leflunomide, Drug: methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: adalimumab, Drug: leflunomide, Drug: methotrexate, Drug: placebo | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: leflunomide, Drug: methotrexate, Drug: placebo | Intervention Type: DRUG; Name: MLTA3698A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: leflunomide; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, C
B: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate
C: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
D: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only

Answer: D